Showing results (721-730 of 756) with videos related to
Sort By:
Pageof 76
Journal of Internal Medicine|March 28, 2018
Targeting Alzheimer's disease with gene and cell therapiesR Loera-Valencia, A Piras, M A M Ismail, et al.Journal of Internal Medicine|May 12, 2016
Current and future treatment of amyloid diseasesM Ankarcrona, B Winblad, C Monteiro, et al.Journal of Neuropathology and Experimental Neurology|July 11, 2000
Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann diseaseG Simic, D Seso-Simic, P J Lucassen, et al.Neurology|March 7, 2008
Safety and efficacy of galantamine in subjects with mild cognitive impairmentB Winblad, S Gauthier, L Scinto, et al.Dementia and Geriatric Cognitive Disorders|June 5, 2003
Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairmentD Religa, M Styczynska, B Peplonska, et al.Archives of Neurology|December 26, 2001
Current concepts in mild cognitive impairmentR C Petersen, R Doody, A Kurz, et al.Journal of Internal Medicine|September 29, 2018
Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementiaB Petek, M Villa-Lopez, R Loera-Valencia, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 8, 1999
NK cell triggering by the human costimulatory molecules CD80 and CD86J L Wilson, J Charo, A Martín-Fontecha, et al.Alzheimer Disease and Associated Disorders|October 15, 1998
Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilitiesA Nordberg, K Amberla, M Shigeta, et al.Journal of Cellular and Molecular Medicine|January 23, 2008
Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathologyR Liu, X-W Zhou, H Tanila, et al.Pageof 76